Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease

Peters, Christopher A.; Cesaretti, Jamie A.; Stone, Nelson N.; Stock, Richard G.

doi:10.1016/j.ijrobp.2006.05.027

Cited by 44 publications

(20 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Brachytherapy exploits the physical characteristics inherent with this modality of radiotherapy, whereby the high radiation dose is limited to the neoplasm target, while the surrounding normal tissues are spared from radiation by the rapid dose reduction (with the square of the distance). Brachytherapy alone, in the therapy of low-risk prostate carcinoma, is well tolerated, even in patients with a history of IBD [101] . Another related treatment, such as intensitymodulated radiotherapy (IMRT), uses sophisticated planning techniques to avoid critical structures.…”

Section: Prevention Of Radiation Colitismentioning

confidence: 99%

Recent advances in the management of radiation colitis

Kountouras¹,

Zavos²

2008

WJG

View full text Add to dashboard Cite

show abstract

Section: Prevention Of Radiation Colitismentioning

confidence: 99%

Recent advances in the management of radiation colitis

Kountouras¹,

Zavos²

2008

WJG

View full text Add to dashboard Cite

show abstract

“…To our knowledge only five retrospective studies including more than 15 IBD patients who received pelvic RT have been published until now (6,9,(15)(16)(17). It is noteworthy that these reports mostly described GI toxicity related to the treatment but no focus was made on IBD activity by using standardized scores as HB and Mayo index.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, Song et al identified 17 IBD patients who received a median dose of 45 Gy of RT delivered to the pelvis or abdomen with (n=15) or without (n=2) concomitant systemic chemotherapy and they described 21% and 8% of grade 3/4 acute and late GI toxicity, respectively (9). Finally, GI toxicity of BT in IBD patients was assessed in the study by Peters et al, who reported only mild to moderate side effects without any grade 3/4 GI toxicity in a population of men with prostate cancer (16). As such, the inclusion of patients treated with BT may have contributed to the lower rates of acute and late GI toxicity in our study.…”

Section: Discussionmentioning

confidence: 99%

“…As such, the inclusion of patients treated with BT may have contributed to the lower rates of acute and late GI toxicity in our study. Indeed, several reports suggested that such a RT technique could be safer in IBD patients, notably by reducing the dose delivered to the small intestine (16,18,19). It is noteworthy that none of these studies have reported any death from GI toxicity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy

Annède¹,

Seisen²,

Klotz³

et al. 2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

Background: Few studies with contradictory results have been published on the safety of pelvic radiation therapy (RT) in patients with inflammatory bowel disease (IBD).Methods: From 1989 to 2015, a single center retrospective analysis was performed including all IBD patients who received pelvic external beam radiation therapy (EBRT) or brachytherapy (BT) for a pelvic malignancy. Treatment characteristics, IBD activity and gastrointestinal (GI) toxicity were examined.Results: Overall, 28 patients with Crohn's disease (CD) (n=13) or ulcerative colitis (n=15) were included in the present study. Median follow-up time after irradiation was 5.9 years. Regarding IBD activity, only one and two patients experienced a severe episode within and after 6 months of follow-up, respectively.Grade 3/4 acute GI toxicity occurred in 3 (11%) patients, whereas one (3.6%) patient experienced late grade 3/4 GI toxicity. Only patients with rectal IBD location (P=0.016) or low body mass index (BMI) (P=0.012) experienced more severe IBD activity within or after 6 months following RT, respectively. Conclusions:We report an acceptable tolerance of RT in IBD patients with pelvic malignancies.Specifically, a low risk of uncontrolled flare-up was observed.

show abstract

“…Dosadašnja su istraživanja, uključujući i ona koja obuhvaćaju bolesnike te istraživanja provedena na životinjskim modelima upalnih bolesti crijeva, pokazala da proteaze imaju važnu, ali još nedovoljno jasnu ulogu u patogenezi UBC-a (48,49). Pokazano je da peptidaze stanične površine imaju presudnu ulogu u razgradnji medijatora uključenih u održavanje integriteta sluznice, kao i u nastanku upalnih promjena (50,51).…”

Section: Patogeneza Upalnih Bolesti Crijevaunclassified

Dipeptidyl Peptidase IV in Inflammatory Bowel Diseases (DPP IV/CD26)

Pučar

Detel

Varljen

2012

Archives of Industrial Hygiene and Toxicology

View full text Add to dashboard Cite

Dipeptidil-peptidaza IV (DPP IV/CD26) i upalne bolesti crijevaUpalne bolesti crijeva (Crohnova bolest, ulcerozni kolitis, nedeterminirani kolitis) skupina su kroničnih autoimunosnih upalnih bolesti obilježenih ponavljanim upalama različitih dijelova gastrointestinalnog trakta koje su važan javnozdravstveni problem današnjice. Unatoč brojnim temeljnim i kliničkim istraživanjima etiologija ovih bolesti, kao i sama patogeneza upale ostaju nedovoljno razjašnjene. Dosadašnja su istraživanja potvrdila uzročno-posljedičnu vezu između medijatora upalnog odgovora i molekula uključenih u regulaciju njihove biološke aktivnosti, osobito proteaza. Cilj ovoga preglednog rada jest sažeti prikaz dosadašnjih saznanja o različitim aspektima upalnih bolesti crijeva, s posebnim naglaskom na potencijalnu ulogu i uključenost dipeptidil-peptidaze IV, odnosno molekule CD26 (DPP IV/CD26) u mehanizme nastanka upalnih procesa u probavnom sustavu. Dan je i pregled životinjskih modela kolitisa koji su znatno pridonijeli razumijevanju i terapiji ovih bolesti, s osobitim naglaskom na mišji model ulceroznog kolitisa (DSS-kolitis) te Crohnove bolesti (TNBS-kolitis).

show abstract

Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease

Cited by 44 publications

References 25 publications

Recent advances in the management of radiation colitis

Recent advances in the management of radiation colitis

Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy

Dipeptidyl Peptidase IV in Inflammatory Bowel Diseases (DPP IV/CD26)

Contact Info

Product

Resources

About